Predictive models for type 2 diabetes onset in middle-aged subjects with the metabolic syndrome

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Ozery Flato, Michal ^a   Parush, Naama ^a   El Hay, Tal ^a   Visockiene, Žydrune ^b   Ryliškyte, Ligita ^b   Badariene, Jolita ^b   Solovjova, Svetlana ^b   Kovaite, Milda ^b   Navickas, Rokas ^b   Laucevičius, Aleksandras ^b  

^a IBM HAIFA RESEARCH LAB   (Israel)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Arterial markers; Biomarkers; Metabolic syndrome; Predictive models; Risk assessment; Type 2 diabetes mellitus

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

ACCURACY; ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RECEIVER OPERATING CHARACTERISTIC;

EID: 84880103647     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-36     Document Type: Article

References (46)

1. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, Arterioscler Thromb Vasc Biol 2004 24 13 e18 14766739
2. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, De Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG, Lancet 2008 371 1927 1935 10.1016/S0140-6736(08)60602-9 18501419
3. The metabolic syndrome. Eckel RH, Grundy SM, Zimmet PZ, Lancet 2005 365 1415 1428 10.1016/S0140-6736(05)66378-7 15836891
4. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Hanson RL, Imperatore G, Bennett PH, Knowler WC, Diabetes 2002 51 3120 3127 10.2337/diabetes.51.10.3120 12351457
5. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, Cardiol Rev 2005 13 322 327 16708441
6. Metabolic syndrome and incident diabetes: current state of the evidence. Ford ES, Li C, Sattar N, Diabetes Care 2008 31 1898 1904 10.2337/dc08-0423 18591398
7. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB, Circulation 2005 112 3066 3072 10.1161/CIRCULATIONAHA.105.539528 16275870
8. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn TA, Colagiuri S, Tonkin AM, Shaw JE, J Intern Med 2008 264 177 186 10.1111/j.1365-2796.2008. 01935.x 18298479
9. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Buijsse B, Simmons RK, Griffin SJ, Schulze MB, Epidemiol Rev 2011 33 46 62 10.1093/epirev/mxq019 21622851
10. Development of diabetes in Chinese with the metabolic syndrome: a 6-year prospective study. Cheung BMY, Wat NMS, Man YB, Tam S, Thomas GN, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, Lam TH, Lam KSL, Diabetes Care 2007 30 1430 1436 10.2337/dc06-1820 17337491
11. Risk factors for type 2 diabetes in groups stratified according to metabolic syndrome: a 10-year follow-up of the Tromsø Study. Joseph J, Svartberg J, Njølstad I, Schirmer H, Eur J Epidemiol 2011 26 117 124 10.1007/s10654-010-9540-7 21188479
12. Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study. Wassink AMJ, Van der Graaf Y, Van Haeften TW, Spiering W, Soedamah-Muthu SS, Visseren FLJ, Diabet Med 2011 28 932 940 10.1111/j.1464-5491.2011.03318.x 21749443
13. Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme-rationale and design. Laucevičius A, Kasiulevičius V, Jatužis D, Petrulionienė Ž Ryliškytė L, Rinkūnienė E, Badarienė J, Čypienė A, Gustienė O, Šlapikas R, Semin Cardiol 2012 18 1 6
14. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, Eur Heart J 2003 24 987 1003 10.1016/S0195-668X(03)00114-3 12788299
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection Evaluation and Treatment of High Blood, Cholesterol in Adults, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
16. Follow-up report on the diagnosis of diabetes mellitus. Genuth S, Alberti KGMM, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, Diabetes Care 2003 26 3160 3167 14578255
17. Enzymatic determination of total serum cholesterol. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC, Clin Chem 1974 20 470 475 4818200
18. Enzymatic determination of total cholesterol in serum. Roeschlau P, Bernt E, Gruber W, Z Klin Chem Klin Biochem 1974 12 226 4440115
19. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Fossati P, Prencipe L, Clin Chem 1982 28 2077 2080 6812986
20. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. McGowan MW, Artiss JD, Strandbergh DR, Zak B, Clin Chem 1983 29 538 542 6825269
21. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 499 502 4337382
22. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Alberti KG, Zimmet PZ, Diabet Med 1998 15 539 553 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S 9686693
23. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825
24. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ, J Clin Endocrinol Metab 2000 85 2402 2410 10.1210/jc.85.7.2402 10902785
25. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Cederholm J, Wibell L, Diabetes Res Clin Pract 1990 10 167 175 10.1016/0168-8227(90)90040-Z 2261853
26. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Matsuda M, DeFronzo RA, Diabetes Care 1999 22 1462 1470 10.2337/diacare.22.9.1462 10480510
27. Reduced time points to calculate the composite index. DeFronzo RA, Matsuda M, Diabetes Care 2010 33 93 10.2337/dc10-0646 20587713
28. A Test of Missing Completely at Random for Multivariate Data with Missing Values. Little RJA, J Am Stat Assoc 1988 83 1198 1202 10.1080/01621459.1988. 10478722
29. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR, BMJ 2009 338 2393 10.1136/bmj.b2393 19564179
30. Rubin DB, Multiple Imputation for Nonresponse in Surveys New York, USA: John Willey & Sons 1987
31. Multiple imputation of discrete and continuous data by fully conditional specification. Van Buuren S, Stat Methods Med Res 2007 16 219 242 10.1177/0962280206074463 17621469
32. Missing data: Our view of the state of the art. Schafer JL, Graham JW, Psychological Methods 2002 7 147 177 12090408
33. Estimating the Dimension of a Model. Schwarz G, Ann Statist 1978 6 461 464 10.1214/aos/1176344136
34. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Unwin N, Shaw J, Zimmet P, Alberti KGMM, Diabet Med 2002 19 708 723 12207806
35. Population-based incidence of type 2 diabetes in northern Spain: the Asturias Study. Valdés S, Botas P, Delgado E, Alvarez F, Cadórniga FD, Diabetes Care 2007 30 2258 2263 10.2337/dc06-2461 17536076
36. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L, Diabetes Care 2009 32 281 286 19017778
37. Predicting the 20-year diabetes incidence rate. Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I, Diabetes Metab Res Rev 2007 23 551 558 10.1002/dmrr.728 17315136
38. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Stern MP, Williams K, Haffner SM, Ann Intern Med 2002 136 575 581 10.7326/0003-4819-136-8-200204160-00006 11955025
39. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. Norberg M, Eriksson JW, Lindahl B, Andersson C, Rolandsson O, Stenlund H, Weinehall L, J Intern Med 2006 260 263 271 10.1111/j.1365-2796.2006.01689.x 16918824
40. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, Eschwege E, Diabetes Care 2006 29 1619 1625 10.2337/dc05-2525 16801588
41. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, Kambe H, Diabetes Care 2009 32 644 646 10.2337/dc08-1631 19131461
42. Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction: a 6-year community-based prospective study. Choi SH, Kim TH, Lim S, Park KS, Jang HC, Cho NH, Diabetes Care 2011 34 944 949 10.2337/dc10-0644 21335372
43. Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes. Tanabe N, Saito K, Yamada Y, Takasawa T, Seki N, Suzuki H, Intern Med 2009 48 401 409 10.2169/internalmedicine.48.1325 19293537
44. Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. Lacy PS, O'Brien DG, Stanley AG, Dewar MM, Swales PPR, Williams B, J Hypertens 2004 22 1937 1944 10.1097/00004872-200410000-00016 15361765
45. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? The DECODE Study Group, European Diabetes Epidemiology Group, Diabetes Care 2003 26 688 696 10.2337/diacare.26.3.688 12610023
46. What is the best predictor of future type 2 diabetes? Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M, Diabetes Care 2007 30 1544 1548 10.2337/dc06-1331 17384342